Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cereno Scientific ABFRA:4A1 +4.69%39 Piotroski F-Score is 3 as of Aug. 02, 2026, which is 50% above its 10-year median of 2.00. GuruFocus rates FRA:4A1 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review. Among 979 Drug Manufacturers companies, Cereno Scientific AB ranks worse than 78.35% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Cereno Scientific AB has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Cereno Scientific AB's Piotroski F-Score or its related term are showing as below:
FRA:4A1'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 2 Max: 5
Current: 3
During the past 11 years, the highest Piotroski F-Score of Cereno Scientific AB was 5. The lowest was 1. And the median was 2.
Cereno Scientific AB (FRA:4A1) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Cereno Scientific AB Piotroski F-Score Related Terms
Cereno Scientific AB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Cereno Scientific AB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cereno Scientific AB Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Cereno Scientific AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Cereno Scientific AB's current Net Income (TTM) was -11.12.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Cereno Scientific AB's return on assets of this year was -0.32203783. Cereno Scientific AB's return on assets of last year was -0.40549612.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Cereno Scientific AB's gearing of this year was 0.44508671. Cereno Scientific AB's gearing of last year was 0.53388836.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Cereno Scientific AB's current ratio of this year was 2.19936909. Cereno Scientific AB's current ratio of last year was 2.64450764.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Cereno Scientific AB's number of shares in issue this year was 334.597. Cereno Scientific AB's number of shares in issue last year was 309.159.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Cereno Scientific AB's gross margin of this year was . Cereno Scientific AB's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Cereno Scientific AB's asset turnover of this year was 0. Cereno Scientific AB's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Cereno Scientific AB has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Cereno Scientific AB (FRA:4A1) has a Piotroski F-Score of 3 as of Aug. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Cereno Scientific AB and its competitors. This is 50% above median its historical median of 2.00. Over the past decade, Cereno Scientific AB's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, Cereno Scientific AB ranks #767 out of 979 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Cereno Scientific AB's Piotroski F-Score too high?
Cereno Scientific AB's current Piotroski F-Score of 3 is 50% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Cereno Scientific AB's value of 3 is 40% below this industry median. Based on the distribution chart, Cereno Scientific AB ranks #767 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cereno Scientific AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Cereno Scientific AB's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cereno Scientific AB ranks #767 out of 979 companies for Piotroski F-Score. This places Cereno Scientific AB in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Cereno Scientific AB's value of 3 is 40% below this benchmark. Historically, Cereno Scientific AB's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 5.00, Cereno Scientific AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cereno Scientific AB's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Cereno Scientific AB and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cereno Scientific AB's current Piotroski F-Score is 3, which is 50% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cereno Scientific AB stock overvalued right now?
Cereno Scientific AB (FRA:4A1) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3, which is 50% above median its 10-year median of 2.00 and 40% below the Drug Manufacturers industry median of 5.00. Cereno Scientific AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Cereno Scientific AB (FRA:4A1), the current Piotroski F-Score is 3 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. It also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
39GF Score
Get the complete analysis for FRA:4A1
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4A1 has been successfully added to your 
